News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,578 Results
Type
Article (13797)
Company Profile (101)
Press Release (251680)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88054)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6294)
Job Trends (6200)
News (150236)
Policy (14039)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23224)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (38)
Approvals (6330)
Artificial intelligence (106)
Autoimmune disease (9)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (16)
Breast cancer (78)
Cancer (602)
Cardiovascular disease (71)
Career advice (407)
Career pathing (11)
CAR-T (22)
Cell therapy (87)
Cervical cancer (4)
Clinical research (30911)
Collaboration (336)
Compensation (152)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (121)
Cystic fibrosis (37)
Data (625)
Denatured (15)
Depression (9)
Diabetes (78)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (64)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32113)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37458)
Executive appointments (383)
FDA (6709)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (209)
Gene editing (38)
Generative AI (9)
Gene therapy (100)
GLP-1 (347)
Government (1298)
Grass and pollen (2)
Guidances (16)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (792)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5875)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (11)
Layoffs (180)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (80)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (151)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9673)
Metabolic disorders (257)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (574)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (702)
Now hiring (7)
Obesity (147)
Opinion (119)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (46)
Partnered (7)
Patents (115)
Patient recruitment (28)
Peanut (10)
People (28935)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8043)
Phase II (13077)
Phase III (11737)
Pipeline (437)
Policy (70)
Postmarket research (1401)
Preclinical (3214)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (167)
Real estate (2637)
Recruiting (17)
Regulatory (10107)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (36)
Series A (36)
Series B (12)
Service/supplier (3)
Sickle cell disease (32)
Southern California (715)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (31)
Tariffs (21)
The Weekly (30)
United States (7131)
Vaccines (152)
Venture capitalists (14)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Today (3)
Last 7 days (175)
Last 30 days (837)
Last 365 days (11812)
2025 (3437)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20112)
Australia (2612)
California (1701)
Canada (901)
China (235)
Colorado (66)
Connecticut (67)
Delaware (54)
Europe (39422)
Florida (322)
Georgia (38)
Idaho (9)
Illinois (195)
India (16)
Indiana (133)
Iowa (1)
Japan (91)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (252)
Massachusetts (1469)
Michigan (30)
Minnesota (93)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (761)
New Mexico (7)
New York (499)
North Carolina (386)
North Dakota (2)
Northern California (702)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (436)
Puerto Rico (8)
Rhode Island (9)
South America (502)
South Carolina (2)
Southern California (715)
Tennessee (34)
Texas (227)
Utah (33)
Virginia (72)
Washington D.C. (31)
Washington State (116)
Wisconsin (15)
265,578 Results for "supernus pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Depression
Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study
After SPN-820’s failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s therapy Onapgo to sustain the company.
February 20, 2025
·
2 min read
·
Tristan Manalac
BioCapital
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Supernus Pharmaceuticals, Inc. announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET at the Marriott Marquis Hotel in New York City.
May 30, 2024
·
4 min read
Press Releases
Supernus to Participate in Two Upcoming March 2025 Investor Conferences
March 5, 2025
·
4 min read
Press Releases
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
February 27, 2025
·
4 min read
Press Releases
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
·
19 min read
Press Releases
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 12, 2025
·
1 min read
Press Releases
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
November 14, 2024
·
4 min read
Press Releases
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
February 18, 2025
·
4 min read
Press Releases
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
February 4, 2025
·
14 min read
BioCapital
Supernus to Participate in Two Upcoming March 2024 Investor Conferences
Supernus Pharmaceuticals, Inc. announced that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:
March 6, 2024
·
4 min read
1 of 26,558
Next
